Surfactant Therapy

Its key mechanical effect occurs at the alveolar surface, where the delivered material spreads and lowers surface tension. This reduction makes it easier for alveoli to remain open as the lungs empty, limiting repeated collapse. The resulting improvement in lung stability supports more effective ventilation and helps reduce the work associated with breathing in affected premature infants.

Improved compliance means the lungs can expand more readily with less pressure. After surface tension is reduced, ventilation may become more effective because the alveoli remain open and respond better to respiratory support. This change can lessen breathing difficulty and contribute to improved gas exchange, although clinicians continue to manage oxygen exposure and respiratory assistance carefully.

The treatment supplies a lipid- and protein-rich material that functions at the boundary between air and the alveolar surface. Its clinically important effect is the spreading of this material across that surface, where it lowers surface tension. The overview does not assign separate functions to individual lipids or proteins, so their combined surface activity is the supported focus.

Surfactant Therapy complements rather than replaces respiratory support in the described clinical setting. Clinicians administer it while providing appropriate assistance for breathing and monitoring oxygen management. This combined approach aims to stabilize alveoli, improve ventilation, and avoid relying on poorly controlled oxygen exposure. The therapy therefore functions as one part of broader neonatal respiratory care.

For premature infants with respiratory distress syndrome, exogenous surfactant is delivered directly into the trachea so it can reach the lungs and spread across the alveolar surface. Treatment is coordinated with respiratory support and careful oxygen management. The source describes this direct airway route but does not specify a particular device, dose, formulation, or administration schedule.

The primary clinical use is in premature infants whose respiratory distress syndrome results from insufficient surfactant production. In this group, the treatment addresses a specific contributor to neonatal respiratory failure by restoring surface activity in the alveoli. Its use occurs alongside supportive respiratory care, with the goal of reducing breathing difficulty and related complications.

Clinicians can assess whether breathing difficulty decreases and whether lung compliance and ventilation improve after treatment. These changes indicate that the alveoli are functioning more effectively and that gas exchange may be better supported. Surfactant Therapy can also reduce complications associated with neonatal respiratory failure, but the overview does not provide specific response measures or outcome timelines.

Yes. Although its established context in the source is neonatal respiratory distress syndrome caused by insufficient surfactant production, ongoing research is examining possible roles in other forms of acute lung injury. That research reflects the broader principle that impaired alveolar surface function may be clinically relevant beyond prematurity, while the overview does not identify specific additional diseases or confirmed benefits.